论文部分内容阅读
目的：探讨胃癌前病变病理改变的性质、程度和幽门螺杆菌（ＨＰ）感染及药物治疗与其变化过程的关系。方法：胃镜活检慢性萎缩性胃炎（萎缩）３７例，伴肠上皮化生（肠化）１９例、不典型增生７例，观察其与ＨＰ关系，ＨＰ以Ｇｉｍｅｓａ染色，肠化者以粘液组织化学染色。１９例萎缩伴肠化服德诺２８ｄ加施尔康６个月，ＨＰ阳性者加阿莫西林１４ｄ治疗，常规胃镜查ＨＰ根除率。随访６～３１．５个月复查胃镜及ＨＰ。结果：萎缩、肠化、不典型增生ＨＰ阳性率分别为８６．５％（３２／３７）、７８．９％（１５／１９）和５７．１％（４／７）。１９例萎缩伴肠化ＨＰ根除率为６６．７％（１０／１５），萎缩、炎症、肠化改善有效率分别为６３．２％（１２／１９）、７３．７％（１４／１９）和７８．９％（１５／１９）。其中已根除ＨＰ者分别占６６．７％（８／１２）、７１．４％（１０／１４）和６６．７％（１０／１５），与未根除ＨＰ者炎症与肠化改善例数比较有显著性差异（Ｐ＜０．０１）。结论：胃癌前病变与ＨＰ关系密切，联合抗ＨＰ药物及多种维生素疗法对改善胃癌前病变有效。
Objective: To investigate the nature and extent of the pathological changes of gastric precancerous lesions, and the relationship between Helicobacter pylori (HP) infection and drug treatment and its changing process. Methods: Gastric biopsy was performed in 37 cases of chronic atrophic gastritis (atrophy), 19 cases of intestinal metaplasia (intestinal metaplasia), and 7 cases of atypical hyperplasia. The relationship between HP and HP was observed. HP was stained with Gimesa, and intestinal metaplasia was mucinous histochemistry. dyeing. Nineteen patients with atrophy with intestinal metabolites Deno 28d plus sircon 6 months, HP positive plus amoxicillin 14d treatment, routine gastroscopy HP eradication rate. Follow-up 6 to 31.5 months review of gastroscopy and HP. Results: The positive rate of HP in atrophic, intestinal metastasis and atypical hyperplasia were 86.5% (32/37), 78.9% (15/19) and 57.1% (4/7), respectively. 19 cases of atrophic with HP eradication rate of 66.7% (10/15), atrophy, inflammation, intestinal metastasis improved efficiency were 63.2% (12/19), 73.7% (14/19) And 78.9% (15/19). Among them, 66.7% (8/12), 71.4% (10/14), and 66.7% (10/15) of the HP eradication cases were compared with the cases of inflammation and intestinal metastasis in the unerased HP group. There was a significant difference (P<0.01). Conclusion: Precancerous lesions are closely related to HP, combined with anti-HP drugs and multivitamin therapy are effective for improving precancerous lesions.